A Study of Efficacy & Safety of Supaglutide in Type 2 Diabetes Patients On

Status Active, not recruiting

Clinical Trial Summary

This is a study to evaluate the efficacy and safety of Supaglutide injection in the treatment of type 2 diabetes patients with poor glycemic control after metformin treatment. This trial includes dosage determination (Phase IIb) and efficacy confirmation stage(Phase III ). The primary outcome of the phase IIb period is to preliminarily evaluate the efficacy and safety of Supaglutide combined with metformin and to provide the recommended dosage for the Phase 3 period after 12-week treatment. The primary outcome of the Phase III period is to evaluate the efficacy and safety of Supaglutide combined with metformin treatment after 24-week, double-blind treatment. The secondary outcome is to evaluate the efficacy and safety of Supaglutide combined with metformin during the 24-week, double-blinded plus 28-week, open-label treatment period.

Clinical Trial Description

This trial includes a 2-week screening period, a 4-week metformin titration and dose-stabilization period, a 4-week induction period, a 24-week double-blind treatment period and a 28-week open-label treatment period, followed by a 4-week follow-up period and a follow-up visit. We calculated that the sample size would need to be 632, including 120 subjects in the period of Phase IIb and 512 subjects in the period of Phase III. During the phase IIb period, subjects were randomly assigned to once-weekly subcutaneously injected Supaglutide 1mg plus metformin, 3mg plus metformin and placebo plus metformin at a ratio of 1:1:1. When the number of participants who have completed the 12-week follow up reached 120, interim analyses will be performed and the results will be evaluated by Independent Data Monitoring Committee experts to determine the recommended phase 3 dosage. During the phase III stage, subjects were randomly assigned 1:1 to the "recommended phase 3 dosage + metformin" group and the "placebo + metformin" group. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04998032
Study type	Interventional
Source	Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 2/Phase 3
Start date	October 12, 2021
Completion date	August 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03239366` - A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population	Phase 2
Completed	`NCT04597229` - Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus	N/A
Completed	`NCT03623139` - Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes	N/A
Active, not recruiting	`NCT04599920` - Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life)	N/A
Active, not recruiting	`NCT03422471` - Hypoglycemia and Autonomic Nervous System Function- B2	N/A
Completed	`NCT04382521` - A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions	N/A
Recruiting	`NCT04564391` - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins	N/A
Recruiting	`NCT03458715` - The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin	Phase 4
Terminated	`NCT03278236` - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?	N/A
Completed	`NCT02974504` - Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)	Phase 4
Completed	`NCT05053828` - Type 2 Diabetes With Antiplatelet Drugs
Not yet recruiting	`NCT03659383` - The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine	Phase 4
Completed	`NCT03542240` - Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome	N/A
Completed	`NCT03657537` - Effects of Ketone Bodies on Cognition in Type 2 Diabetes	Phase 1
Completed	`NCT03979768` - Risk Assessment of Type 2 Diabetes in Pharmacies	N/A
Completed	`NCT03614039` - Effect of Probiotic and Smectite Gel on NAFLD	N/A
Active, not recruiting	`NCT04994288` - A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients	Phase 2/Phase 3
Completed	`NCT03290768` - Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)	N/A
Enrolling by invitation	`NCT04088851` - "The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes"	N/A
Completed	`NCT03643783` - Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients On Metformin Treatment

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms